A Randomized, Parallel-Group, Open-Label Trial of Recombinant Human Erythropoietin vs Preoperative Autologous Donation in Primary Total Joint Arthroplasty

2007 ◽  
Vol 22 (3) ◽  
pp. 325-333 ◽  
Author(s):  
E. Michael Keating ◽  
John J. Callaghan ◽  
Amar S. Ranawat ◽  
Kiran Bhirangi ◽  
Chitranjan S. Ranawat
Keyword(s):  
Total Joint Arthroplasty ◽  
Recombinant Human Erythropoietin ◽  
Joint Arthroplasty ◽  
Open Label ◽  
Human Erythropoietin ◽  
Parallel Group ◽  
Open Label Trial ◽  
Preoperative Autologous Donation

Daily consumption of fermented soymilk helps to improve facial wrinkles in healthy postmenopausal women in a randomized, parallel-group, open-label trial

2018 ◽  
Vol 8 (2) ◽  
pp. 107 ◽  
Author(s):  
Mitsuyoshi Kano ◽  
Kazuyoshi Haga ◽  
Kouji Miyazaki ◽  
Fumiyasu Ishikawa
Keyword(s):  
Postmenopausal Women ◽  
Maximum Depth ◽  
Liquid Chromatography Mass Spectrometry ◽  
Daily Consumption ◽  
Open Label ◽  
Facial Wrinkle ◽  
Crow’S Feet ◽  
Parallel Group ◽  
Secondary Endpoints ◽  
Open Label Trial

Background: Soymilk fermented by lactobacilli and/or bifidobacteria is attracting attention due to the excellent bioavailability of its isoflavones. We investigated the effects of fermented soymilk containing high amounts of isoflavone aglycones on facial wrinkles and urinary isoflavones in postmenopausal women in a randomized, parallel-group, open-label trial. Healthy Japanese women were randomly divided into active (n = 44, mean age 56.3 ± 0.5) or control (n = 44, mean age 56.1 ± 0.5) groups, who consumed or did not consume a bottle of soymilk fermented by Bifidobacterium breve strain Yakult and Lactobacillus mali for 8 weeks. Maximum depth of wrinkles around the crow’s feet area and other wrinkle parameters were evaluated as primary and secondary endpoints respectively at weeks 0, 4, and 8 during the consumption period. Urinary isoflavone levels were determined by liquid chromatography-mass spectrometry. Results: The active group demonstrated significant improvements in the maximum depth (p=0.015) and average depth (p=0.04) of wrinkles, and significantly elevated urinary isoflavones (daidzein, genistein, and glycitein; each p < 0.001) compared with the control during the consumption period. No serious adverse effects were recorded.Conclusion: These findings suggest that fermented soymilk taken daily may improve facial wrinkles and elevate urinary isoflavones in healthy postmenopausal women.Key words: postmenopausal women; isoflavone; fermented soymilk; phytoestrogen; facial wrinkle 

The Minimal Effective Dosage of Recombinant Human Erythropoietin for Preoperative Autologous Donation

1996 ◽  
Vol 31 (5) ◽  
pp. 640
Author(s):  
Sang hwan Do ◽  
Young jin Lim ◽  
Hyun sung Cho ◽  
Ji ho Lee ◽  
Jong hyun Yoon ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Effective Dosage ◽  
Human Erythropoietin ◽  
Preoperative Autologous Donation

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

The Lancet ◽  
2009 ◽  
Vol 374 (9683) ◽  
pp. 39-47 ◽  
Author(s):  
John B Buse ◽  
Julio Rosenstock ◽  
Giorgio Sesti ◽  
Wolfgang E Schmidt ◽  
Eduard Montanya ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Open Label ◽  
Parallel Group ◽  
Open Label Trial

Preoperative Autologous Donation for Total Joint Arthroplasty

2000 ◽  
Vol 82 (1) ◽  
pp. 89-100 ◽  
Author(s):  
ARMODIOS M. HATZIDAKIS ◽  
R. MICHAEL MENDLICK ◽  
TRACY McKILLIP ◽  
RAM L. REDDY ◽  
KEVIN L. GARVIN
Keyword(s):  
Total Joint Arthroplasty ◽  
Joint Arthroplasty ◽  
Preoperative Autologous Donation

scholarly journals Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes [see comments]

Blood ◽  
1991 ◽  
Vol 78 (7) ◽  
pp. 1658-1663 ◽  
Author(s):  
RS Stein ◽  
RI Abels ◽  
SB Krantz
Keyword(s):  
Myelodysplastic Syndromes ◽  
Recombinant Human Erythropoietin ◽  
Refractory Anemia ◽  
Double Blind Trial ◽  
Open Label ◽  
Double Blind ◽  
Open Label Study ◽  
Label Study ◽  
Human Erythropoietin ◽  
High Doses

Abstract Twenty patients with myelodysplastic syndromes (MDS) entered a randomized, placebo-controlled, double-blind trial designed to evaluate the efficacy and toxicity of high doses of recombinant human erythropoietin (rhEPO). Patients completing the trial were eligible to receive rhEPO as part of an open-label study. Eighteen patients were transfusion dependent; 10 had refractory anemia (RA), and 10 had refractory anemia with ringed sideroblasts (RARS). A response to rhEPO was defined as an increase in hematocrit of 4 percentage points or more over baseline, or the elimination of all transfusions with the hematocrit stable at the baseline level. In the double-blind trial, 1 patient (12.5%) receiving rhEPO responded, as compared with no responses in the placebo group. Overall, responses occurred in 4 of 17 patients (24%) receiving rhEPO at a dose of 1,200 to 1,600 U/kg intravenously (IV) twice weekly. Changes in granulocyte or platelet counts were not observed. Despite the administration of high doses of rhEPO, toxicity attributable to rhEPO was not observed in either the double-blind or open-label study. Response to rhEPO was not significantly related to age, gender, type of MDS, time since diagnosis, time since initiation of transfusion therapy, or baseline serum EPO. These studies indicate that rhEPO can be administered safely in very high doses to patients with MDS and that 24% of these patients will respond with increased erythropoiesis.

Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial

2004 ◽  
Vol 22 (7) ◽  
pp. 1301-1307 ◽  
Author(s):  
Michael Auerbach ◽  
Harold Ballard ◽  
J. Richard Trout ◽  
Marilyn McIlwain ◽  
Alan Ackerman ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Cancer Patients ◽  
Recombinant Human Erythropoietin ◽  
Transferrin Saturation ◽  
Oral Iron ◽  
Iron Dextran ◽  
Iron Group ◽  
Open Label ◽  
Human Erythropoietin ◽  
Iv Iron

PurposeRecombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized trials in cancer patients.MethodsThis prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb ≤ 105 g/L, serum ferritin ≤ 450 pmol/L or ≤ 675 pmol/L with transferrin saturation ≤ 19%) receiving subcutaneously rHuEPO 40,000 U once weekly to: (1) no-iron; (2) oral iron 325 mg twice daily; (3) iron dextran repeated 100mg IV bolus; or (4) iron dextran total dose infusion (TDI). Hb and quality of life (QOL) were measured at baseline and throughout.ResultsAll groups showed Hb (P < .0001) increases from baseline. Mean Hb increases for both IV iron groups were greater (P < .02) than for no-iron and oral iron groups. The percentage of patients with hematopoietic responses was higher (P < .01) in both IV iron groups (each case 68%) compared with no-iron (25%) and oral iron (36%) groups. IV iron groups showed increases in energy, activity, and overall QOL from baseline, compared with a decrease in energy and activity for no-iron group and no change in activity or overall QOL for oral iron group.ConclusionrHuEPO increases Hb levels and improves QOL in patients with chemotherapy-related anemia. Magnitude of Hb increase and QOL improvement is significantly greater if IV iron is added.

Sign in / Sign up

Export Citation Format

Share Document